Laiyang Jiangbo Pharmaceuticals

Laiyang Jiangbo Pharmaceuticals is a Chinese pharmaceutical company that specialized in the development and manufacturing of Western and traditional Chinese herbal medicines. The company gained prominence through its US-listed holding company, Jiangbo Pharmaceuticals, Inc., which was listed on NASDAQ in 2010 following a reverse merger. However, the company became a central figure in a major accounting scandal involving 'China-concept stocks,' leading to its delisting in 2011 after an SEC investigation revealed misrepresented cash balances and management obstruction. Its commercial portfolio included antibiotics like Clarithromycin and gastrointestinal treatments like Itopride, while its R&D pipeline featured LFAA, a novel cardiovascular candidate. The company's operations effectively ceased to be relevant to the international investment community after its SEC registration was revoked in 2013.